Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo.
We have previously shown that peroxisome proliferator activating receptor ß/δ (PPAR β/δ is overexpressed in psoriasis. PPAR β/δ is not present in adult epidermis of mice. Targeted expression of PPAR β/δ and activation by a selective synthetic agonist is sufficient to induce an inflammatory skin dise...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0037097&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214185111126016 |
|---|---|
| author | Katrin Hack Louise Reilly Colin Palmer Kevin D Read Suzanne Norval Robert Kime Kally Booth John Foerster |
| author_facet | Katrin Hack Louise Reilly Colin Palmer Kevin D Read Suzanne Norval Robert Kime Kally Booth John Foerster |
| author_sort | Katrin Hack |
| collection | DOAJ |
| description | We have previously shown that peroxisome proliferator activating receptor ß/δ (PPAR β/δ is overexpressed in psoriasis. PPAR β/δ is not present in adult epidermis of mice. Targeted expression of PPAR β/δ and activation by a selective synthetic agonist is sufficient to induce an inflammatory skin disease resembling psoriasis. Several signalling pathways dysregulated in psoriasis are replicated in this model, suggesting that PPAR β/δ activation contributes to psoriasis pathogenesis. Thus, inhibition of PPAR β/δ might harbour therapeutical potential. Since PPAR β/δ has pleiotropic functions in metabolism, skin-targeted inhibition offer the potential of reducing systemic adverse effects. Here, we report that three selective PPAR β/δ antagonists, GSK0660, compound 3 h, and GSK3787 can be formulated for topical application to the skin and that their skin concentration can be accurately quantified using ultra-high performance liquid chromatography (UPLC)/mass spectrometry. These antagonists show efficacy in our transgenic mouse model in reducing psoriasis-like changes triggered by activation of PPAR β/δ. PPAR β/δ antagonists GSK0660 and compound 3 do not exhibit systemic drug accumulation after prolonged application to the skin, nor do they induce inflammatory or irritant changes. Significantly, the irreversible PPAR β/δ antagonist (GSK3787) retains efficacy when applied topically only three times per week which could be of practical clinical usefulness. Our data suggest that topical inhibition of PPAR β/δ to treat psoriasis may warrant further exploration. |
| format | Article |
| id | doaj-art-5e464c15485647c3b214801eaed238d6 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5e464c15485647c3b214801eaed238d62025-08-20T02:08:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0175e3709710.1371/journal.pone.0037097Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo.Katrin HackLouise ReillyColin PalmerKevin D ReadSuzanne NorvalRobert KimeKally BoothJohn FoersterWe have previously shown that peroxisome proliferator activating receptor ß/δ (PPAR β/δ is overexpressed in psoriasis. PPAR β/δ is not present in adult epidermis of mice. Targeted expression of PPAR β/δ and activation by a selective synthetic agonist is sufficient to induce an inflammatory skin disease resembling psoriasis. Several signalling pathways dysregulated in psoriasis are replicated in this model, suggesting that PPAR β/δ activation contributes to psoriasis pathogenesis. Thus, inhibition of PPAR β/δ might harbour therapeutical potential. Since PPAR β/δ has pleiotropic functions in metabolism, skin-targeted inhibition offer the potential of reducing systemic adverse effects. Here, we report that three selective PPAR β/δ antagonists, GSK0660, compound 3 h, and GSK3787 can be formulated for topical application to the skin and that their skin concentration can be accurately quantified using ultra-high performance liquid chromatography (UPLC)/mass spectrometry. These antagonists show efficacy in our transgenic mouse model in reducing psoriasis-like changes triggered by activation of PPAR β/δ. PPAR β/δ antagonists GSK0660 and compound 3 do not exhibit systemic drug accumulation after prolonged application to the skin, nor do they induce inflammatory or irritant changes. Significantly, the irreversible PPAR β/δ antagonist (GSK3787) retains efficacy when applied topically only three times per week which could be of practical clinical usefulness. Our data suggest that topical inhibition of PPAR β/δ to treat psoriasis may warrant further exploration.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0037097&type=printable |
| spellingShingle | Katrin Hack Louise Reilly Colin Palmer Kevin D Read Suzanne Norval Robert Kime Kally Booth John Foerster Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo. PLoS ONE |
| title | Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo. |
| title_full | Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo. |
| title_fullStr | Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo. |
| title_full_unstemmed | Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo. |
| title_short | Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo. |
| title_sort | skin targeted inhibition of ppar β δ by selective antagonists to treat ppar β δ mediated psoriasis like skin disease in vivo |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0037097&type=printable |
| work_keys_str_mv | AT katrinhack skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT louisereilly skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT colinpalmer skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT kevindread skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT suzannenorval skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT robertkime skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT kallybooth skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo AT johnfoerster skintargetedinhibitionofpparbdbyselectiveantagoniststotreatpparbdmediatedpsoriasislikeskindiseaseinvivo |